Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) - USD ($)	Apr. 12, 2024	Jun. 30, 2024
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		$ 154,393,000
Strategic Collaboration and License Agreement
Revenue
Amount of cumulative catch-up adjustment at the date of the termination	$ 101,348,000
Aggregate remaining transaction price that had not yet been recognized as revenue	$ 146,301,000
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		24,515,000
Strategic Collaboration and License Agreement \| Research Service Rights Granted for Initial Off the Shelf Collaboration Targets
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		7,926,000
Strategic Collaboration and License Agreement \| Research Service Rights Granted for Personalized Therapies
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		5,086,000
Strategic Collaboration and License Agreement \| Material Right to Designate the Additional Off the Shelf Collaboration Target
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		7,764,000
Strategic Collaboration and License Agreement \| Material Right for First Option Extend the Research Term
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		2,991,000
Strategic Collaboration and License Agreement \| Material Right for Second Option Extend the Research Term
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements		$ 748,000